New study to monitor MenQuadfi® vaccine safety in thousands

NCT ID NCT07621653

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 05, 2026 · Last updated Jun 10, 2026 · Updated 1 time

Summary

This study is checking the safety of the MenQuadfi® vaccine, which protects against four types of meningococcal disease. About 706 healthy people aged 6 weeks to 55 years in South Korea will be watched for side effects after getting the vaccine in regular clinics. The goal is to find any unexpected or rare reactions not seen in earlier trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL IMMUNIZATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.